A-F

 

 


ATECTURA® BREEZHALER® (indacaterol (as acetate)/mometasone furoate)

 

 


AZARGA®(brinzolamide / timolol (as timolol maleate))

 

 


CATAFLAM®(diclofenac potassium)

 

 


CILOXAN®(ciprofloxacin hydrochloride)

 

 


CO-DIOVAN®(valsartan/hydrochlorothiazide)

 

 


DESFERAL®(deferoxamine mesilate)

 


DUOTRAV®(timolol maleate/travoprost)

 

 


ENERZAIR® BREEZHALER®(indacaterol/glycopyrronium/mometasone furoate)

 

 


ENTRESTO®(sacubitril/valsartan)

 

 


EUCREAS®(vildagliptin/metformin)

 

 


EXELON®(rivastigmine hydrogen tartrate)

 

 


EXELON® PATCH(rivastigmine)

 

 


EXFORGE®(amlodipine/valsartan)

 

 


EXFORGE® HCT(amlodipine/valsartan/hydrochlorothiazide)

 

 


EXJADE®▼(deferasirox)

 

G-L

 

 


KESIMPTA®(ofatumumab)

 

 


KYMRIAH®(tisagenlecleucel)

 

 


 


LOCAMETZ®▼(gozetotide)

 

 


 


LUXTURNA®▼(voretigene neparvovec)

 

 


LYSAKARE®(l-arginine/l-lysine)

 

M-R

 

MAXIDEX®(dexamethasone)

 

 


MAXITROL®(dexamethasone/polymyxin b sulfate/neomycin sulfate)

 

 


 


 


MYFORTIC®(mycophenolic acid)

 

 


ONBREZ® BREEZHALER®(indacaterol)

 

 


OPATANOL®(olopatadine (as hydrochloride))

 

 


 


S-Z

 

SANDIMMUN®(ciclosporin)

 

 


SANDOSTATIN®/SANDOSTATIN LAR®(octreotide)

 

 


SCEMBLIX®(asciminib hydrochloride)

 

 


SEEBRI® BREEZHALER®(glycopyrronium)

 

 


SIMBRINZA®(brinzolamide/brimonidine tartrate)

 

 


 


 


 


TEGRETOL®(carbamazepine)

 

 


 


TRILEPTAL®(oxcarbazepine)

 

 


ULTIBRO® BREEZHALER®(indacaterol/glycopyrronium)

 

 


VOLTAROL®(diclofenac sodium)

 

 


ZOLGENSMA®(onasemnogene abeparvovec)

 

 

May 2025 | FA-11427176

Reporting of side effects:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.